Volume 2020, Issue 1 8819757

Research Article

Open Access

Nephroprotective Effect of Mesenchymal Stem Cell-Based Therapy of Kidney Disease Induced by Toxicants

Shujun Lin

Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, 515041 Shantou, China stu.edu.cn

Search for more papers by this author

Wenshan Lin,

Wenshan Lin

Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, 515041 Shantou, China stu.edu.cn

Search for more papers by this author

Chunling Liao,

Chunling Liao

Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, 515041 Shantou, China stu.edu.cn

Search for more papers by this author

Tianbiao Zhou,

Corresponding Author

Tianbiao Zhou

[email protected]

orcid.org/0000-0001-8065-1644

Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, 515041 Shantou, China stu.edu.cn

Search for more papers by this author

Shujun Lin,

Shujun Lin

Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, 515041 Shantou, China stu.edu.cn

Search for more papers by this author

Wenshan Lin,

Wenshan Lin

Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, 515041 Shantou, China stu.edu.cn

Search for more papers by this author

Chunling Liao,

Chunling Liao

Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, 515041 Shantou, China stu.edu.cn

Search for more papers by this author

Tianbiao Zhou,

Corresponding Author

Tianbiao Zhou

[email protected]

orcid.org/0000-0001-8065-1644

Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, 515041 Shantou, China stu.edu.cn

Search for more papers by this author

First published: 23 December 2020

https://doi.org/10.1155/2020/8819757

Citations: 4

Academic Editor: Erika B. Rangel

Share a link

Email
Wechat
Bluesky

Abstract

Background. Renal damage caused by drug toxicity is becoming increasingly common in the clinic. Preventing and treating kidney damage caused by drug toxicity are essential to maintain patient health and reduce the social and economic burden. In this study, we performed a meta-analysis to assess the nephroprotective effect of mesenchymal stem cells (MSCs) in the treatment of kidney disease induced by toxicants. Methods. The Cochrane Library, Embase, ISI Web of Science, and PubMed databases were searched up to December 31, 2019, to identify studies and extract data to assess the efficacy of MSCs treatment of kidney disease induced by toxicants using Cochrane Review Manager Version 5.3. A total of 27 studies were eligible and selected for this meta-analysis. Results. The results showed that a difference in serum creatinine levels between the MSC treatment group and control group was observed for 2, 4, 5, 6-8, 10-15, 28-30, and ≥42 days (2 days: WMD = −0.88, 95% CI: -1.34, -0.42, P = 0.0002; 4 days: WMD = −0.74, 95% CI: -0.95, -0.54, P < 0.00001; 5 days: WMD = −0.46, 95% CI: -0.67, -0.25, P < 0.0001; 6-8 days: WMD = −0.55, 95% CI: -0.84, -0.26, P = 0.0002; 10-15 days: WMD = −0.37, 95% CI: -0.53, -0.20, P < 0.0001; 28-30 days: WMD = −0.53, 95% CI: -1.04, -0.02, P = 0.04; ≥42 days: WMD = −0.22, 95% CI: -0.39, -0.06, P = 0.007). Furthermore, a difference in blood urea nitrogen levels between the MSC treatment group and control group was observed for 2-3, 4-5, 6-8, and ≥28 days. The results also indicate that MSC treatment alleviated inflammatory cells, necrotic tubules, regenerative tubules, and renal interstitial fibrosis in kidney disease induced by toxicants. Conclusion. MSCs may be a promising therapeutic agent for kidney disease induced by toxicants.

1. Introduction

Kidney injury occurs during acute kidney injury (AKI) and chronic kidney disease (CKD), and it is a common condition associated with the morbidity and mortality of patients. A total of 80% of patients who survive an AKI episode completely recover kidney function, and recovered AKI patients present an almost 9-fold increase in risk for CKD development [1]. Toxicant-induced kidney injury is one of the most common causes of kidney disease, causing substantial morbidity and hampering drug development [2]. At present, renal damage caused by drug toxicity is becoming increasingly common in the clinic. Preventing and treating kidney damage caused by drug toxicity is essential to maintain patient health and reduce the social and economic burden.

Mesenchymal stem cells (MSCs), which are multipotent mesenchymal cells present in various tissues, have multilineage differentiation ability under appropriate conditions and are easy to obtain. They are a promising therapeutic option for some diseases because of their unique property of releasing some important bioactive factors [3–5]. Drug toxicity can induce renal tubular epithelial cell damage or death and can lead to renal interstitial inflammation, which eventually develops into renal interstitial fibrosis and renal loss. Previous studies have shown that MSCs can play a protective role against injury of renal tubular epithelial cells and prevent renal interstitial fibrosis [6–10]. Before clinical application, animal experiments in vivo are generally required to confirm the effectiveness of MSCs. Furthermore, there are few clinical trials of MSCs on kidney disease induced by toxicants. Therefore, in this study, we performed a meta-analysis to assess the nephroprotective effect of MSCs in the treatment of kidney disease induced by toxicants in animals.

2. Materials and Methods

2.1. Search Strategy

We searched databases (Cochrane Library, Embase, ISI Web of Science, and PubMed) up to Dec 31, 2019, using the following search terms: (mesenchymal stem cells OR MSC OR MSCs OR multipotent stromal cells OR mesenchymal stromal cells OR mesenchymal progenitor cells OR stem cells) AND (gentamicin OR aristolochic acid OR cisplatin OR adriamycin OR cadmium chloride OR methotrexate OR rifampicin OR glycerol OR streptozocin) AND (kidney injury OR renal failure OR kidney disease). The search was confined to English-language literature. An additional search was conducted among the eligible manual references of the cited articles.

2.2. Inclusion and Exclusion Criteria

Our meta-analysis included studies analyzing the efficacy of MSC treatment in mice or rats with kidney disease. The following studies were excluded from the analysis: (1) letters, case reports, reviews, clinical studies, editorials, meta-analysis, and systematic reviews; (2) studies lacking the targeted indicators or number of case or control groups and were conducted in humans; (3) studies of kidney disease that was not induced by toxicants; and (4) studies with therapeutic regimen for kidney disease that included other agents with undefined effects.

2.3. Outcome Measures

We filtered the following outcomes associated with the efficacy of MSC treatment from the recruited studies: serum creatinine (Scr), blood urea nitrogen (BUN), urinary albumin excretion (UAE), malondialdehyde (MDA), L-glutathione (GSH), superoxide dismutase (SOD), and renal pathology. In addition, we conducted a mutual consensus when met with disagreements.

2.4. Quality Assessment

Two investigators independently evaluated the methodological quality using the Cochrane Handbook for Interventions. We assessed the following sections of every investigation: selection bias, attrition bias, performance bias, detection bias, reporting bias, and other bias. Each item was classified as unclear, high risk, or low risk.

2.5. Statistical Analysis

Review Manager Version 5.3 was applied to explore whether MSC treatment achieved a good efficacy in kidney disease induced by toxicants, and STATA 12.0 was used to test the publication bias. Heterogeneity of variation among individual studies was quantified and described using I². The fixed effects model was used if the P value of the heterogeneity test was ≥ 0.1. Otherwise, the random effects model was applied to pool the outcomes. In addition, to compute continuous variables, we analyzed weighted mean differences (WMDs) for the mean values. We also calculated 95% confidence intervals (95% CI) for the included studies using the Mantel-Haenszel (M-H) method. Additionally, we evaluated the publication bias using Begg’s rank correlation test as well as Egger’s linear regression method among the studies. A P value < 0.05 was considered of statistical significance.

3. Results

3.1. Search Results

The databases mentioned above were searched, and only studies in mice or rats that evaluated the therapeutic efficacy of MSC treatment on kidney disease induced by toxicants were selected. Twenty-seven studies [11–37] were eligible and selected for this meta-analysis, and a flowchart of inclusion of studies is presented in Figure 1. Study characteristics are shown in Table 1.

Details are in the caption following the image — **Figure 1**
Open in figure viewer PowerPoint

Flow diagram of the selection process.

Table 1. Characteristics of the studies included in this meta-analysis.

Author, year	n	Type of animal	Type of injury	MSC type	Number of MSC	Route of delivery	Endpoints for this meta-analysis
Herrera 2004	24	Mice	Glycerol-induced	BM-MSCs	1 × 10⁶	Intravenous injection	Scr
Bi 2007	12	Mice	Cisplatin-induced	BM-MSCs	2 × 10⁵	Intravenous injection or intraperitoneal injection	Scr, BUN
Sun 2008	40	Rat	Glycerol-induced	BM-MSCs	2 × 10⁶	Abdominal aorta injection	Scr, BUN
Qian 2008	6	Rat	Glycerol-induced	BM-MSCs	1 × 10⁴	Intravenous injection	Scr
Magnasco 2008	22	Rat	Adriamycin-induced	BM-MSCs	3 × 10⁶	Intravenous injection	Scr, BUN, UAE, renal damage score
Bruno 2009	16	Mice	Glycerol-induced	BM-MSCs	—	Intravenous injection	Scr, BUN, MDA, GSH, SOD, renal damage score
Eliopoulos 2010	10	Mice	Cisplatin-induced	BM-MSCs	5 × 10⁶	Intraperitoneal injection	Scr, BUN
Kim 2012	17	Rat	Cisplatin-induced	AD-MSCs	5 × 10⁵	Intravenous injection	Scr, BUN
Zickri 2012	30	Rat	Adriamycin-induced	hUC-MSCs	5 × 10⁵	Intravenous injection	Scr
Sarhan 2014	19	Rat	Adriamycin-induced	BM-MSCs	4 × 10⁶	Intravenous injection	Scr, BUN, UAE, renal pathology, MDA, GSH
Moustafa 2016	80	Rat	Cisplatin-induced	BM-MSCs	5 × 10⁶	Intravenous, intraarterial or kidney subcapsular injection	Scr, MDA, GSH, SOD
Elhusseini 2016	40	Rat	Cisplatin-induced	AD-MSCs	5 × 10⁶	Intravenous injection	Scr, BUN, Ccr, renal pathology, MDA, GSH, SOD
Anan 2016	13	Rat	Adriamycin-induced	BM-MSCs	1 × 10⁶	Intravenous injection	Scr, BUN, SOD
Gad 2017	24	Rat	Methotrexate-induced	BM-MSCs	2 × 10⁶	Intraperitoneal injection	Scr, BUN, MDA, GSH
Rashed 2018	20	Rat	Streptozotocin -induced	BM-MSCs	1 × 10⁶	Intravenous injection	Scr, BUN, UAE, Ccr
Elbaghdady 2018	20	Rat	Cadmium chloride-induced	BM-MSCs	2 × 10⁶	Intravenous injection	Scr
Danjuma 2018	16	Rat	Rifampicin-induced	BM-MSCs	2.5 × 10⁵	Intravenous injection	Scr, BUN
Putra 2019	10	Rat	Gentamicin induced	hUC-MSCs	1 × 10⁶	Intraperitoneal injection	Scr, BUN, renal pathology
Cetinkaya 2019	17	Rat	Aristolochic acid induced	hAMSC	6 × 10⁵	Intravenous injection	Scr, BUN
Selim 2019	70	Rat	Cisplatin-induced	AD-MSCs; BM-MSCs	4 × 10⁶	Intravenous injection	Scr, BUN
Mata-Miranda 2019	10	Mice	Cisplatin-induced	mESCs	1 × 10⁶	Intraperitoneal injection	Scr
Vazquez-Zapien 2019	19	Mice	Cisplatin-induced	mESCs	1 × 10⁶	Intraperitoneal injection	Scr
Minocha 2019	3	Rat	Cisplatin-induced	AFSC	2 × 10⁶	Intravenous injection	Scr, BUN
Sun B 2019	10	Rat	Cisplatin-induced	USCs	2 × 10⁶	Intravenous injection	Scr
Sun 2019	6	Rat	Cisplatin-induced	BM-MSCs	—	Renal parenchyma injection	Scr, BUN
Zhang 2020	9	Rat	Cisplatin-induced	USCs	5 × 10⁶	Subcutaneous injection	Scr, Ccr, renal pathology
Foroutan 2020	6	Rat	Cisplatin-induced	BM-MSCs	—	Intraperitoneal injection	Scr, BUN

Note: BM-MSCs: bone marrow mesenchymal stem cells; hAMSCs: human amnion-derived mesenchymal stem cells; hUC-MSCs: human umbilical cord-mesenchymal stem cells; AD-MSCs: adipose tissue-derived mesenchymal stem cells; mESCs: mouse embryonic stem cells; AFSCs: amniotic fluid stem cells; USCs: urine-derived stem cells; Scr: serum creatinine; BUN: blood urea nitrogen; UAE: urinary albumin excretion; Ccr: creatinine clearance rate; MDA: malondialdehyde; GSH: L-glutathione; SOD: superoxide dismutase.

3.2. Quality Assessment of Included Studies

The methodological quality of the selected studies was considered acceptable because most study domains were ranked as unclear risk or low risk of bias. Unclear risk of bias was mostly detected in performance and selection bias. Low risk of bias mostly occurred in detection, reporting, and attrition bias. Figure 2 shows a summary of the risk of biases of the selected studies.

3.3. Scr

A total of 27 studies [11–37] were selected to assess the effect of MSCs on Scr, and the results show that a difference between the MSC treatment and control groups was observed for 2, 4, 5, 6-8, 10-15, 28-30 days, and ≥42 days (2 days: WMD = −0.88, 95% CI: -1.34, -0.42, P = 0.0002; 4 days: WMD = −0.74, 95% CI: -0.95, -0.54, P < 0.00001; 5 days: WMD = −0.46, 95% CI: -0.67, -0.25, P < 0.0001; 6-8 days: WMD = −0.55, 95% CI: -0.84, -0.26, P = 0.0002; 10-15 days: WMD = −0.37, 95% CI: -0.53, -0.20, P < 0.0001; 28-30 days: WMD = −0.53, 95% CI: -1.04, -0.02, P = 0.04; ≥42 days: WMD = −0.22, 95% CI: -0.39, -0.06, P = 0.007; Figure 3 and Table 2). However, no difference was observed between the MSC treatment and control groups for 3 days (3 days: WMD = −0.09, 95% CI: -0.25, -0.06, P = 0.24; Figure 3 and Table 2).

Table 2. Meta-analysis of the efficacy of MSC in therapy of renal injury induced by toxicant.

Indicators	Time point	Studies	Q test	Model	OR/WMD	P
Indicators	Time point	number	P value	selected	(95% CI)
Scr	2 days	3	0.001	Random	-0.88 (-1.34, -0.42)	0.0002
	3 days	4	0.0004	Random	-0.09 (-0.25, 0.06)	0.24
	4 days	6	0.0002	Random	-0.74 (-0.95, -0.54)	<0.00001
	5 days	6	<0.00001	Random	-0.46 (-0.67, -0.25)	<0.0001
	6-8 days	7	<0.00001	Random	-0.55 (-0.84, -0.26)	0.0002
	10-15 days	11	<0.00001	Random	-0.37 (-0.53, -0.20)	<0.0001
	28-30 days	7	<0.00001	Random	-0.53 (-1.04, -0.02)	0.04
	≥42 days	6	<0.00001	Random	-0.22 (-0.39, -0.06)	0.007
BUN	2-3 days	6	<0.00001	Random	-25.08 (-37.49, -12.67)	<0.0001
	4-5 days	8	<0.00001	Random	-45.71 (-59.36, -32.05)	<0.00001
	6-8 days	5	<0.00001	Random	-57.55 (-99.19, -15.91)	0.007
	13-15 days	4	<0.00001	Random	-13.40 (-32.34, 5.54)	0.17
	≥28 days	8	<0.00001	Random	-23.39 (-36.39, -10.40)	0.0004
UAE	—	3	0.72	Fixed	-22.66 (-26.41, -18.90)	<0.00001
MDA	—	4	0.41	Fixed	-17.21 (-20.38, -14.04)	<0.00001
GSH	—	4	<0.00001	Random	4.62 (2.74, 6.50)	<0.00001
SOD	—	3	<0.00001	Random	5.42 (2.92, 7.93)	<0.0001
Renal pathology
Inflammatory cells	—	4	<0.00001	Random	-2.66 (-3.83, -1.49)	<0.00001
Necrotic tubule	—	2	<0.00001	Random	-2.58 (-4.75, -0.40)	0.02
Regenerative tubules	—	2	—	Fixed	6.00 (3.45, 8.55)	<0.00001
Renal interstitial fibrosis	—	3	<0.00001	Random	-5.82 (-7.41, -4.23)	<0.00001

Note: Scr: serum creatinine; BUN: blood urea nitrogen; UAE: urinary albumin excretion; Ccr: creatinine clearance rate; MDA: malondialdehyde; GSH: L-glutathione; SOD: superoxide dismutase.

3.4. BUN

A total of 18 studies [11–15, 17–19, 21, 22, 24, 26–29, 32–34, 36, 37] were selected to assess the effect of MSCs on BUN, and the results indicate that the difference between the MSC treatment and control groups was observed for 2-3, 4-5, 6-8, and ≥28 days (2-3 days: WMD = −25.08, 95% CI: -37.49, -12.67, P < 0.0001; 4-5 days: WMD = −45.71, 95% CI: -59.36, -32.05, P < 0.00001; 6-8 days: WMD = −57.55, 95% CI: -99.19, -15.91, P = 0.007; ≥28 days: WMD = −23.39, 95% CI: -36.39, -10.40, P = 0.0004; Figure 4 and Table 2). However, no difference was observed between the MSC treatment and control groups for 13-15 days (WMD = −13.40, 95% CI: -32.34, 5.54, P = 0.17; Figure 4 and Table 2).

3.5. Urinary Albumin Excretion

Three studies [22, 26, 27] were selected in the meta-analysis for the assessment of MSCs on UAE. The results show that the MSC group had a lower UAE than the control group (WMD = −22.66, 95% CI: -26.41, -18.90, P < 0.00001; Table 2).

3.6. Oxidative Stress

Four studies [17, 19, 23, 27] were selected for the assessment of MDA, four [17, 19, 23, 27] for GSH, and three [11, 17, 23] for SOD. The results indicate that a difference between the MSC treatment and control groups was observed for MDA, GSH, and SOD (MDA: WMD = −17.21, 95% CI: -20.38, -14.04, P < 0.00001; GSH: WMD = 4.62, 95% CI: 2.74, 6.50, P < 0.00001; SOD: WMD = 5.42, 95% CI: 2.92, 7.93, P < 0.0001; Table 2).

3.7. Assessment of Renal Pathology

Four studies [17, 24, 27, 35] for inflammatory cells, two studies [17, 27] for necrotic tubules, two studies [17, 27] for regenerative tubules, and three studies [17, 27, 35] for renal interstitial fibrosis were included in this meta-analysis. The results indicate that the difference in inflammatory cells, necrotic tubules, regenerative tubules, and renal interstitial fibrosis between the MSC treatment and control groups was significant (inflammatory cells: WMD = −2.66, 95% CI: -3.83, -1.49, P < 0.00001; necrotic tubules: WMD = −2.58, 95% CI: -4.75, -0.40, P = 0.02; regenerative tubules: WMD = 6.00, 95% CI: 3.45, 8.55, P < 0.00001; renal interstitial fibrosis: WMD = −5.82, 95% CI: -7.41, -4.23, P < 0.00001; Table 2).

3.8. Publication Bias

Publication bias was tested in this meta-analysis, and a funnel plot generated using STATA 12.0 for the primary outcome. Begg’s test and Egger’s test results suggest that publication bias was present (P ≤ 0.01 and P ≤ 0.01, respectively; Figure 5).

4. Discussion

We reviewed all the selected studies and evaluated the Scr, BUN, UAE, oxidative stress, and renal pathology results to assess the nephroprotective effect of MSCs in the treatment of kidney disease induced by toxicants. We found that MSC treatment reduced Scr levels at 2, 4, 5, 6-8, 10-15, 28-30, and ≥42 days and reduced BUN levels at 2-3, 4-5, 6-8, and ≥28 days. We also found that the MSC group had a lower UAE than the control group. It has been previously shown that MSC treatment reduces the levels of Scr, BUN, and proteinuria in lupus nephritis in mice [38]. Chen et al. [39] found that MSC ameliorates ischemia/reperfusion injury-induced acute kidney injury in rats and reduces Scr levels. Xiu et al. [40] found that MSC transplantation significantly reduces the concentration of BUN and Scr, prevents tissue injury, and reduces mortality after lipopolysaccharide-induced acute kidney injury. Clinical trials also supported that MSC injection decreases rejection after transplantation. Tan et al. [41] found that the therapy with MSCs achieve better renal function and lower incidence of acute rejection at 1 year compared with the anti-IL-2 receptor antibody induction. Vanikar et al. [42] demonstrated that infusion of MSCs as well as hematopoietic stem cells eases immunosuppression in living donor renal transplantation. Our previous meta-analysis also found that MSCs reduce Scr levels, BUN levels, and proteinuria, as well as alleviate renal damage in animal models of AKI [43]. Lower proteinuria was also found in patients with SLE after MSC therapy [44].

The MSC treatment group had a higher level of GSH, SOD, and a lower level of MDA when compared with the control group. El-Metwaly et al. [45] found that MSCs increase GSH levels and reduce MDA levels in lung tissue of rats subjected to acute lung injury. Li et al. [46] reported that MSCs can restore the levels of GSH and MDA in rats with chronic alcoholism, and its effects on repairing sciatic nerve were obvious. Liu et al. [47] reported that MSCs significantly increase the activity of glutathione (GSH) and reduce the levels of MDA in rats induced by unilateral ureteral obstruction.

The mechanism by which MSCs repair injured kidneys may be complex. After kidney injury, VCAM-1, GFP, SDF -1/CXCR4, and CD44 are upregulated in the injured tissue, which may play important roles in the migration of MSCs to the damaged area. These substances may be partly secreted by the MSCs themselves [20, 48, 49]. The presence of MSCs may limit the injury and repair the ischemic tubular damage to maintain the glomerular filtration rate and downregulate BUN [50]. In addition, MSCs lower the expression of several proinflammatory cytokines such as TNF-α, IL-1β, and IFN-γ as well as increase anti-inflammatory cytokines such as IL-1, IL-10, Bcl-2, TNF-α, bFGF, and prostaglandin E2 [49, 51]. Another possibility is that MSCs may restore damaged cells and prevent apoptosis by secreting microvesicles, which contain microRNAs, mRNAs, or proteins [49]. To conclude, MSCs can migrate to the damaged tissue, promote the recovery of renal function, enhance proliferation, and reduce fibrosis and inflammation.

Furthermore, our study indicates that MSC treatment can alleviate inflammatory cells, necrotic tubules, regenerative tubules, and renal interstitial fibrosis in kidney disease induced by toxicants. Some previous studies indicated that MSC treatment can alleviate renal pathological changes in unilateral ureteral obstruction rat or mice [9, 10, 52].

However, this meta-analysis also has some limitations. First, a small sample size was found for the recruited studies. The administered dose and the type of MSCs were not exactly the same. Publication bias was found in this meta-analysis, and the results should be reassessed in the future. Furthermore, the studies frequently had different animal models (mouse or rat), toxin doses, and administration routes for renal injury. These limitations may affect the robustness of our results.

5. Conclusions

The MSC treatment reduced Scr levels after 2, 4, 5, 6-8, 10-15, 28-30, and ≥42 days and reduced BUN levels after 2-3, 4-5, 6-8, and ≥28 days. The results also indicate that MSC treatment alleviated the inflammatory cells, necrotic tubules, regenerative tubules, and renal interstitial fibrosis in kidney disease induced by toxicants.

Abbreviations

MSCs:: Mesenchymal stem cells
Scr:: Serum creatinine
BUN:: Blood urea nitrogen
UAE:: Urinary albumin excretion
MDA:: Malondialdehyde
GSH:: L-glutathione
SOD:: Superoxide dismutase
WMDs:: Weighted mean differences
CI:: Confidence intervals
M-H:: Mantel-Haenszel.

Consent

There are no human subjects in this article and informed consent is not applicable.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

TBZ contributed to the conception and design of the study. TBZ and SJL were responsible for collection of data and performing the statistical analysis and manuscript preparation. WSL and CLL were responsible for checking the data. All authors were responsible for drafting the manuscript, read, and approved the final version.

Open Research

Data Availability

The data supporting this meta-analysis are from previously reported studies and datasets, which have been cited. The processed data are available from the corresponding author upon request.

References

1 Basile D. P., Bonventre J. V., Mehta R., Nangaku M., Unwin R., Rosner M. H., Kellum J. A., Ronco C., and ADQI XIII Work Group, Progression after AKI: understanding maladaptive repair processes to predict and identify therapeutic treatments, Journal of the American Society of Nephrology. (2016) 27, no. 3, 687–697, https://doi.org/10.1681/ASN.2015030309, 2-s2.0-84959864378, 26519085.
10.1681/ASN.2015030309
CAS PubMed Web of Science® Google Scholar
2 Pianta T. J., Buckley N. A., Peake P. W., and Endre Z. H., Clinical use of biomarkers for toxicant-induced acute kidney injury, Biomarkers in Medicine. (2013) 7, no. 3, 441–456, https://doi.org/10.2217/bmm.13.51, 2-s2.0-84878743472, 23734808.
10.2217/bmm.13.51
CAS PubMed Web of Science® Google Scholar
3 Liang Y., Zhang D., Li L., Xin T., Zhao Y., Ma R., and Du J., Exosomal microRNA-144 from bone marrow-derived mesenchymal stem cells inhibits the progression of non-small cell lung cancer by targeting CCNE1 and CCNE2, Stem Cell Research & Therapy. (2020) 11, no. 1, https://doi.org/10.1186/s13287-020-1580-7, 32102682.
10.1186/s13287-020-1580-7
PubMed Web of Science® Google Scholar
4 Jasmin, E. Ferrari and M. Soloviev, In vitro labeling mesenchymal stem cells with superparamagnetic iron oxide nanoparticles: efficacy and cytotoxicity, Nanoparticles in Biology and Medicine, 2020, 2118, Humana, New York, NY, 235–250, Methods in Molecular Biology, https://doi.org/10.1007/978-1-0716-0319-2_18.
10.1007/978-1-0716-0319-2_18
Google Scholar
5 Zhu Y., Zhang X., Gu R., Liu X., Wang S., Xia D., Li Z., Lian X., Zhang P., Liu Y., and Zhou Y., LAMA2 regulates the fate commitment of mesenchymal stem cells via hedgehog signaling, Stem Cell Research & Therapy. (2020) 11, no. 1, https://doi.org/10.1186/s13287-020-01631-9, 32213190.
10.1186/s13287-020-01631-9
PubMed Web of Science® Google Scholar
6 He J., Jiang Y. L., Wang Y., Tian X. J., and Sun S. R., Micro-vesicles from mesenchymal stem cells over-expressing miR-34a inhibit transforming growth factor-β1-induced epithelial-mesenchymal transition in renal tubular epithelial cells in vitro, Chinese Medical Journal. (2020) 133, no. 7, 800–807, https://doi.org/10.1097/CM9.0000000000000720.
10.1097/CM9.0000000000000720
CAS PubMed Web of Science® Google Scholar
7 Li D., Zhang D., Tang B., Zhou Y., Guo W., Kang Q., Wang Z., Shen L., Wei G., and He D., Exosomes from human umbilical cord mesenchymal stem cells reduce damage from oxidative stress and the epithelial-mesenchymal transition in renal epithelial cells exposed to oxalate and calcium oxalate monohydrate, Stem Cells International. (2019) 2019, 10, 6935806, https://doi.org/10.1155/2019/6935806, 2-s2.0-85065843972.
10.1155/2019/6935806
PubMed Web of Science® Google Scholar
8 Liu B., Ding F., Hu D., Zhou Y., Long C., Shen L., Zhang Y., Zhang D., and Wei G., Human umbilical cord mesenchymal stem cell conditioned medium attenuates renal fibrosis by reducing inflammation and epithelial-to-mesenchymal transition via the TLR4/NF-κB signaling pathway in vivo and in vitro, Stem Cell Research & Therapy. (2018) 9, no. 1, https://doi.org/10.1186/s13287-017-0760-6, 2-s2.0-85040467869, 29329595.
10.1186/s13287-017-0760-6
PubMed Web of Science® Google Scholar
9 Xing L., Song E., Yu C. Y., Jia X. B., Ma J., Sui M. S., Wang M. A., and Gao X., Bone marrow-derived mesenchymal stem cells attenuate tubulointerstitial injury through multiple mechanisms in UUO model, Journal of Cellular Biochemistry. (2018) 120, no. 6, 9737–9746, https://doi.org/10.1002/jcb.28254, 2-s2.0-85058043914, 30525227.
10.1002/jcb.28254
PubMed Web of Science® Google Scholar
10 Zheng J., Wang Q., Leng W., Sun X., and Peng J., Bone marrow‑derived mesenchymal stem cell‑conditioned medium attenuates tubulointerstitial fibrosis by inhibiting monocyte mobilization in an irreversible model of unilateral ureteral obstruction, Molecular Medicine Reports. (2018) 17, no. 6, 7701–7707, https://doi.org/10.3892/mmr.2018.8848, 2-s2.0-85046551061.
10.3892/mmr.2018.8848
CAS PubMed Web of Science® Google Scholar
11 Anan H. H., Zidan R. A., Shaheen M. A., and Abd- el Fattah E. A., Therapeutic efficacy of bone marrow derived mesenchymal stromal cells versus losartan on adriamycin-induced renal cortical injury in adult albino rats, Cytotherapy. (2016) 18, no. 8, 970–984, https://doi.org/10.1016/j.jcyt.2016.05.004, 2-s2.0-84991672322, 27378342.
10.1016/j.jcyt.2016.05.004
CAS PubMed Web of Science® Google Scholar
12 Bi B., Schmitt R., Israilova M., Nishio H., and Cantley L. G., Stromal cells protect against acute tubular Injuryviaan endocrine effect, Journal of the American Society of Nephrology. (2007) 18, no. 9, 2486–2496, https://doi.org/10.1681/ASN.2007020140, 2-s2.0-34548489620.
10.1681/ASN.2007020140
PubMed Web of Science® Google Scholar
13 Bruno S., Grange C., Deregibus M. C., Calogero R. A., Saviozzi S., Collino F., Morando L., Busca A., Falda M., Bussolati B., Tetta C., and Camussi G., Mesenchymal stem cell-derived microvesicles protect against acute tubular injury, Journal of the American Society of Nephrology. (2009) 20, no. 5, 1053–1067, https://doi.org/10.1681/ASN.2008070798, 2-s2.0-65649089130, 19389847.
10.1681/ASN.2008070798
CAS PubMed Web of Science® Google Scholar
14 Cetinkaya B., Unek G., Kipmen-Korgun D., Koksoy S., and Korgun E. T., Effects of human placental amnion derived mesenchymal stem cells on proliferation and apoptosis mechanisms in chronic kidney disease in the rat, International Journal of Stem Cells. (2019) 12, no. 1, 151–161, https://doi.org/10.15283/ijsc18067, 2-s2.0-85065529988, 30595007.
10.15283/ijsc18067
CAS PubMed Web of Science® Google Scholar
15 Danjuma L., Mok P. L., Higuchi A., Hamat R. A., Teh S. W., Koh A. E., Munusamy M. A., Arulselvan P., Rajan M., Nambi A., Swamy K. B., Vijayaraman K., Murugan K., Natarajaseenivasan K., and Subbiah S. K., Modulatory and regenerative potential of transplanted bone marrow-derived mesenchymal stem cells on rifampicin-induced kidney toxicity, Regenerative Therapy. (2018) 9, 100–110, https://doi.org/10.1016/j.reth.2018.09.001, 2-s2.0-85053758458, 30525080.
10.1016/j.reth.2018.09.001
PubMed Web of Science® Google Scholar
16 Elbaghdady H. A. M., Alwaili M. A., and El-Demerdash R. S., Regenerative potential of bone marrow mesenchymal stem cells on cadmium chloride-induced hepato-renal injury and testicular dysfunction in sprague dawley rats, Ecotoxicology and Environmental Safety. (2018) 164, 41–49, https://doi.org/10.1016/j.ecoenv.2018.07.019, 2-s2.0-85051038496.
10.1016/j.ecoenv.2018.07.019
CAS PubMed Web of Science® Google Scholar
17 Elhusseini F. M., Saad M. A., Anber N., Elghannam D., Sobh M. A., Alsayed A., El-dusoky S., Sheashaa H., Abdel-Ghaffar H., and Sobh M., Long term study of protective mechanisms of human adipose derived mesenchymal stem cells on cisplatin induced kidney injury in Sprague-Daweley rats, Journal of Stem Cells and Regenerative Medicine. (2016) 12, no. 1, 36–48, https://doi.org/10.46582/jsrm.1201006, 27398000.
10.46582/jsrm.1201006
PubMed Web of Science® Google Scholar
18 Eliopoulos N., Zhao J., Bouchentouf M., Forner K., Birman E., Yuan S., Boivin M.-N., and Martineau D., Human marrow-derived mesenchymal stromal cells decrease cisplatin renotoxicity in vitro and in vivo and enhance survival of mice post-intraperitoneal injection, American Journal of Physiology-Renal Physiology. (2010) 299, no. 6, F1288–F1298, https://doi.org/10.1152/ajprenal.00671.2009, 2-s2.0-78649947922, 20844023.
10.1152/ajprenal.00671.2009
CAS PubMed Web of Science® Google Scholar
19 Gad A. M., Hassan W. A., and Fikry E. M., Significant curative functions of the mesenchymal stem cells on methotrexate-induced kidney and liver injuries in rats, Journal of Biochemical and Molecular Toxicology. (2017) 31, no. 8, https://doi.org/10.1002/jbt.21919, 2-s2.0-85018635679.
10.1002/jbt.21919
Web of Science® Google Scholar
20 Herrera M. B., Bussolati B., Bruno S., Fonsato V., Romanazzi G. M., and Camussi G., Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury, International Journal of Molecular Medicine. (2004) 14, no. 6, 1035–1041, https://doi.org/10.3892/ijmm.14.6.1035.
10.3892/ijmm.14.6.1035
PubMed Web of Science® Google Scholar
21 Kim J. H., Park D. J., Yun J. C., Jung M. H., Yeo H. D., Kim H.-J., Kim D. W., Yang J. I., Lee G.-W., Jeong S.-H., Roh G. S., and Chang S.-H., Human adipose tissue-derived mesenchymal stem cells protect kidneys from cisplatin nephrotoxicity in rats, American Journal of Physiology-Renal Physiology. (2012) 302, no. 9, F1141–F1150, https://doi.org/10.1152/ajprenal.00060.2011, 2-s2.0-84860507833, 22205231.
10.1152/ajprenal.00060.2011
CAS PubMed Web of Science® Google Scholar
22 Magnasco A., Corselli M., Bertelli R., Ibatici A., Peresi M., Gaggero G., Cappiello V., Chiavarina B., Mattioli G., Gusmano R., Ravetti J. L., Frassoni F., and Ghiggeri G. M., Mesenchymal stem cells protective effect in adriamycin model of nephropathy, Cell Transplantation. (2008) 17, no. 10-11, 1157–1167, https://doi.org/10.3727/096368908787236567, 2-s2.0-60549115287, 19181210.
10.3727/096368908787236567
PubMed Web of Science® Google Scholar
23 Moustafa F. E., Sobh M. A., Abouelkheir M., Khater Y., Mahmoud K., Saad M. A., and Sobh M. A., Study of the effect of route of administration of mesenchymal stem cells on cisplatin-induced acute kidney injury in Sprague Dawley rats, International Journal of Stem Cells. (2016) 9, no. 1, 79–89, https://doi.org/10.15283/ijsc.2016.9.1.79, 2-s2.0-84970044264, 27426089.
10.15283/ijsc.2016.9.1.79
CAS PubMed Web of Science® Google Scholar
24 Putra A., Pertiwi D., Milla M. N., Indrayani U. D., Jannah D., Sahariyani M., Trisnadi S., and Wibowo J. W., Hypoxia-preconditioned MSCs have superior effect in ameliorating renal function on acute renal failure animal model, Open Access Macedonian Journal of Medical Sciences. (2019) 7, no. 3, 305–310, https://doi.org/10.3889/oamjms.2019.049, 2-s2.0-85066731428, 30833992.
10.3889/oamjms.2019.049
PubMed Google Scholar
25 Qian H., Yang H., Xu W., Yan Y., Chen Q., Zhu W., Cao H., Yin Q., Zhou H., Mao F., and Chen Y., Bone marrow mesenchymal stem cells ameliorate rat acute renal failure by differentiation into renal tubular epithelial-like cells, International Journal of Molecular Medicine. (2008) 22, no. 3, 325–332, 18698491.
PubMed Web of Science® Google Scholar
26 Rashed L. A., Elattar S., Eltablawy N., Ashour H., Mahmoud L. M., and El-Esawy Y., Mesenchymal stem cells pretreated with melatonin ameliorate kidney functions in a rat model of diabetic nephropathy, Biochemistry and Cell Biology. (2018) 96, no. 5, 564–571, https://doi.org/10.1139/bcb-2017-0230, 2-s2.0-85054999108, 29425466.
10.1139/bcb-2017-0230
CAS PubMed Web of Science® Google Scholar
27 Sarhan M., El Serougy H., Hussein A. M., El-Dosoky M., Sobh M. A., Fouad S. A., Sobh M., and Elhusseini F., Impact of bone-marrow-derived mesenchymal stem cells on adriamycin-induced chronic nephropathy, Canadian journal of physiology and pharmacology. (2014) 92, no. 9, 733–743, https://doi.org/10.1139/cjpp-2013-0503, 2-s2.0-84919654575, 25093892.
10.1139/cjpp-2013-0503
CAS PubMed Web of Science® Google Scholar
28 Selim R. E., Ahmed H. H., Abd-Allah S. H., Sabry G. M., Hassan R. E., Khalil W. K. B., and Abouhashem N. S., Mesenchymal stem cells: a promising therapeutic tool for acute kidney injury, Applied Biochemistry and Biotechnology. (2019) 189, no. 1, 284–304, https://doi.org/10.1007/s12010-019-02995-2, 2-s2.0-85064515399.
10.1007/s12010-019-02995-2
CAS PubMed Web of Science® Google Scholar
29 Sun J. H., Teng G. J., Ma Z. L., and Ju S. H., In vivo monitoring of magnetically labeled mesenchymal stem cells administered intravascularly in rat acute renal failure, Swiss Medical Weekly. (2008) 138, no. 27-28, 404–412, 18642136.
PubMed Web of Science® Google Scholar
30 Zickri M. B., Zaghloul S., Farouk M., and Fattah M. M., Effect of stem cell therapy on adriamycin induced tubulointerstitial injury, International Journal of Stem Cells. (2012) 5, no. 2, 130–139, https://doi.org/10.15283/ijsc.2012.5.2.130, 2-s2.0-84875260306.
10.15283/ijsc.2012.5.2.130
CAS PubMed Google Scholar
31 Mata-Miranda M. M., Bernal-Barquero C. E., Martinez-Cuazitl A., Guerrero-Robles C. I., Sanchez-Monroy V., Rojas-Lopez M., and Vazquez-Zapien G. J., Nephroprotective effect of embryonic stem cells reducing lipid peroxidation in kidney injury induced by cisplatin, Oxidative Medicine and Cellular Longevity. (2019) 2019, 14, 5420624, https://doi.org/10.1155/2019/5420624, 2-s2.0-85063544873.
10.1155/2019/5420624
PubMed Web of Science® Google Scholar
32 Vazquez-Zapien G. J., Martinez-Cuazitl A., Rangel-Cova L. S., Camacho-Ibarra A., and Mata-Miranda M. M., Biochemical and histological effects of embryonic stem cells in a mouse model of renal failure, Romanian journal of morphology and embryology. (2019) 60, no. 1, 189–194, 31263844.
PubMed Web of Science® Google Scholar
33 Minocha E., Sinha R. A., Jain M., Chaturvedi C. P., and Nityanand S., Amniotic fluid stem cells ameliorate cisplatin-induced acute renal failure through induction of autophagy and inhibition of apoptosis, Stem Cell Research & Therapy. (2019) 10, no. 1, https://doi.org/10.1186/s13287-019-1476-6, 31801607.
10.1186/s13287-019-1476-6
PubMed Web of Science® Google Scholar
34 Sun B., Luo X., Yang C., Liu P., Yang Y., Dong X., Yang Z., Xu J., Zhang Y., and Li L., Therapeutic effects of human urine-derived stem cells in a rat model of cisplatin-induced acute kidney injury in vivo and in vitro, Stem Cells International. (2019) 2019, 13, 8035076, https://doi.org/10.1155/2019/8035076.
10.1155/2019/8035076
PubMed Web of Science® Google Scholar
35 Zhang C., George S. K., Wu R., Thakker P. U., Abolbashari M., Kim T.-H., Ko I. K., Zhang Y., Sun Y., Jackson J., Lee S. J., Yoo J. J., and Atala A., Reno-protection of urine-derived stem cells in a chronic kidney disease rat model induced by renal ischemia and nephrotoxicity, International Journal of Biological Sciences. (2020) 16, no. 3, 435–446, https://doi.org/10.7150/ijbs.37550, 32015680.
10.7150/ijbs.37550
CAS PubMed Web of Science® Google Scholar
36 Sun W., Zhu Q., Yan L., and Shao F., Mesenchymal stem cells alleviate acute kidney injury via miR-107-mediated regulation of ribosomal protein S19, Annals of Translational Medicine. (2019) 7, no. 23, https://doi.org/10.21037/atm.2019.11.89.
10.21037/atm.2019.11.89
Web of Science® Google Scholar
37 Foroutan T., Nafar M., and Motamedi E., Intraperitoneal injection of graphene oxide nanoparticle accelerates stem cell therapy effects on acute kidney injury, Stem Cells Cloning. (2020) 13, 21–32, https://doi.org/10.2147/sccaa.s212087, 32104004.
10.2147/sccaa.s212087
PubMed Web of Science® Google Scholar
38 Zhou T., Liao C., Li H. Y., Lin W., Lin S., and Zhong H., Efficacy of mesenchymal stem cells in animal models of lupus nephritis: a meta-analysis, Stem Cell Research & Therapy. (2020) 11, no. 1, https://doi.org/10.1186/s13287-019-1538-9, 32019582.
10.1186/s13287-019-1538-9
PubMed Web of Science® Google Scholar
39 Chen Y., Tang X., Li P., Zhou Y., Xue T., Liu J., and Yu C., Bone marrow derived mesenchymal stromal cells ameliorate ischemia/reperfusion injury-induced acute kidney injury in rats via secreting tumor necrosis factor-inducible gene 6 protein, BioMed Research International. (2019) 2019, 12, 9845709, https://doi.org/10.1155/2019/9845709, 2-s2.0-85063541174.
10.1155/2019/9845709
PubMed Web of Science® Google Scholar
40 Xiu G.-H., Zhou X., Li X.-L., Chen X.-Z., Li B.-Q., Chen X.-L., Jin H., Pan X.-H., Sun J., and Ling B., Role of bone marrow mesenchymal stromal cells in attenuating inflammatory reaction in lipopolysaccaride-induced acute kidney injury of rats associated with TLR4-NF-kappa B signaling pathway inhibition, Annals of Clinical & Laboratory Science. (2018) 48, no. 6, 743–750.
CAS PubMed Web of Science® Google Scholar
41 Tan J., Wu W., Xu X., Liao L., Zheng F., Messinger S., Sun X., Chen J., Yang S., Cai J., Gao X., Pileggi A., and Ricordi C., Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial, JAMA. (2012) 307, no. 11, 1169–1177, https://doi.org/10.1001/jama.2012.316, 2-s2.0-84863338204, 22436957.
10.1001/jama.2012.316
CAS PubMed Web of Science® Google Scholar
42 Vanikar A. V., Trivedi H. L., Kumar A., Gopal S. C., Patel H. V., Gumber M. R., Kute V. B., Shah P. R., and Dave S. D., Co-infusion of donor adipose tissue-derived mesenchymal and hematopoietic stem cells helps safe minimization of immunosuppression in renal transplantation - single center experience, Renal Failure. (2014) 36, no. 9, 1376–1384, https://doi.org/10.3109/0886022x.2014.950931, 2-s2.0-84907440929, 25246338.
10.3109/0886022X.2014.950931
CAS PubMed Web of Science® Google Scholar
43 Zhou T., Liao C., Lin S., Lin W., Zhong H., and Huang S., The efficacy of mesenchymal stem cells in therapy of acute kidney injury induced by ischemia-reperfusion in animal models, Stem Cells International. (2020) 2020, 1873921, https://doi.org/10.1155/2020/1873921.
10.1155/2020/1873921
PubMed Web of Science® Google Scholar
44 Zhou T., Li H. Y., Liao C., Lin W., and Lin S., Clinical efficacy and safety of mesenchymal stem cells for systemic lupus erythematosus, Stem Cells International. (2020) 2020, 11, 6518508, https://doi.org/10.1155/2020/6518508, 32322279.
10.1155/2020/6518508
PubMed Web of Science® Google Scholar
45 El-Metwaly S., El-Senduny F. F., El-Demerdash R. S., and Abdel-Aziz A. F., Mesenchymal stem cells alleviate hydrochloric acid-induced lung injury through suppression of inflammation, oxidative stress and apoptosis in comparison to moxifloxacin and sildenafil, Heliyon. (2019) 5, no. 12, https://doi.org/10.1016/j.heliyon.2019.e02710, 31872097.
10.1016/j.heliyon.2019.e02710
PubMed Web of Science® Google Scholar
46 Li P., Chen Y., Yang K., Chen D., and Kong D., Mechanical characteristics of BMSCs-intervened sciatic nerve in chronic alcohol-intoxicated animal model, International Journal of Neuroscience. (2020) 1–7, https://doi.org/10.1080/00207454.2020.1750397.
10.1080/00207454.2020.1750397
Web of Science® Google Scholar
47 Liu B., Ding F.-X., Liu Y., Xiong G., Lin T., He D.-W., Zhang Y.-Y., Zhang D.-Y., and Wei G.-H., Human umbilical cord-derived mesenchymal stem cells conditioned medium attenuate interstitial fibrosis and stimulate the repair of tubular epithelial cells in an irreversible model of unilateral ureteral obstruction, Nephrology. (2018) 23, no. 8, 728–736, https://doi.org/10.1111/nep.13099, 2-s2.0-85050771740, 28667820.
10.1111/nep.13099
CAS PubMed Web of Science® Google Scholar
48 Togel F. E. and Westenfelder C., Mesenchymal stem cells: a new therapeutic tool for AKI, Nature reviews. Nephrology. (2010) 6, no. 3, 179–183, https://doi.org/10.1038/nrneph.2009.229, 2-s2.0-77649091092, 20186233.
10.1038/nrneph.2009.229
PubMed Web of Science® Google Scholar
49 Barnes C. J., Distaso C. T., Spitz K. M., Verdun V. A., and Haramati A., Comparison of stem cell therapies for acute kidney injury, American Journal of Stem Cells. (2016) 5, no. 1, 1–10, 27335697.
PubMed Web of Science® Google Scholar
50 Kale S., Karihaloo A., Clark P. R., Kashgarian M., Krause D. S., and Cantley L. G., Bone marrow stem cells contribute to repair of the ischemically injured renal tubule, Journal of Clinical Investigation. (2003) 112, no. 1, 42–49, https://doi.org/10.1172/jci17856, 2-s2.0-85047689644, 12824456.
10.1172/JCI17856
CAS PubMed Web of Science® Google Scholar
51 Togel F., Hu Z., Weiss K., Isaac J., Lange C., and Westenfelder C., Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms, American Journal of Physiology-Renal Physiology. (2005) 289, no. 1, F31–F42, https://doi.org/10.1152/ajprenal.00007.2005, 2-s2.0-20844440562, 15713913.
10.1152/ajprenal.00007.2005
CAS PubMed Web of Science® Google Scholar
52 Wang Z., Li S., Wang Y., Zhang X., Chen L., and Sun D., GDNF enhances the anti-inflammatory effect of human adipose-derived mesenchymal stem cell-based therapy in renal interstitial fibrosis, Stem Cell Research. (2019) 41, article 101605, https://doi.org/10.1016/j.scr.2019.101605.
10.1016/j.scr.2019.101605
Web of Science® Google Scholar

Citing Literature

All articles

Nephroprotective Effect of Mesenchymal Stem Cell-Based Therapy of Kidney Disease Induced by Toxicants

Abstract

1. Introduction